6.15
price up icon5.85%   0.34
after-market アフターアワーズ: 6.14 -0.01 -0.16%
loading
前日終値:
$5.81
開ける:
$5.95
24時間の取引高:
2.68M
Relative Volume:
1.55
時価総額:
$463.22M
収益:
$13.38M
当期純損益:
$-241.11M
株価収益率:
-1.4442
EPS:
-4.2584
ネットキャッシュフロー:
$-140.93M
1週間 パフォーマンス:
+7.52%
1か月 パフォーマンス:
-2.07%
6か月 パフォーマンス:
-42.90%
1年 パフォーマンス:
+2.50%
1日の値動き範囲:
Value
$5.80
$6.41
1週間の範囲:
Value
$5.55
$6.41
52週間の値動き範囲:
Value
$4.01
$11.24

Verastem Inc Stock (VSTM) Company Profile

Name
名前
Verastem Inc
Name
セクター
Healthcare (1108)
Name
電話
(781) 292-4200
Name
住所
117 KENDRICK STREET, NEEDHAM, MA
Name
職員
78
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
VSTM's Discussions on Twitter

Compare VSTM vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VSTM
Verastem Inc
6.15 437.61M 13.38M -241.11M -140.93M -4.2584
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.82 121.40B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
764.93 83.25B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
728.11 46.39B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.51 43.41B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
292.94 33.09B 5.36B 287.73M 924.18M 2.5229

Verastem Inc Stock (VSTM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-04 開始されました H.C. Wainwright Buy
2025-10-16 再開されました Cantor Fitzgerald Overweight
2025-04-10 開始されました Jefferies Buy
2025-03-24 繰り返されました H.C. Wainwright Buy
2024-12-31 繰り返されました BTIG Research Buy
2024-09-30 開始されました Guggenheim Buy
2023-11-21 再開されました BTIG Research Buy
2023-09-27 開始されました B. Riley Securities Buy
2023-06-15 アップグレード Mizuho Neutral → Buy
2022-09-07 再開されました Alliance Global Partners Buy
2022-04-29 再開されました Cantor Fitzgerald Overweight
2022-04-14 開始されました RBC Capital Mkts Outperform
2022-03-09 開始されました Truist Buy
2021-07-01 開始されました Alliance Global Partners Buy
2021-05-24 アップグレード BTIG Research Neutral → Buy
2019-06-20 ダウングレード BTIG Research Buy → Neutral
2019-05-10 ダウングレード Raymond James Outperform → Mkt Perform
2018-07-13 開始されました BTIG Research Buy
2018-05-02 開始されました Seaport Global Securities Buy
2018-03-08 開始されました B. Riley FBR, Inc. Buy
2017-09-07 繰り返されました H.C. Wainwright Buy
2017-04-13 開始されました Oppenheimer Outperform
2017-03-24 繰り返されました H.C. Wainwright Buy
2015-09-29 ダウングレード Cantor Fitzgerald Buy → Hold
2015-09-29 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 ダウングレード Jefferies Buy → Hold
2015-09-29 ダウングレード Raymond James Strong Buy → Outperform
2015-09-28 ダウングレード Mizuho Buy → Neutral
2015-09-28 ダウングレード ROTH Capital Buy → Neutral
2015-09-09 開始されました Raymond James Strong Buy
2015-05-12 繰り返されました UBS Buy
2015-04-08 開始されました H.C. Wainwright Buy
2015-01-23 繰り返されました ROTH Capital Buy
2014-07-08 再開されました Oppenheimer Perform
2014-02-11 開始されました Mizuho Buy
すべてを表示

Verastem Inc (VSTM) 最新ニュース

pulisher
12:19 PM

Verastem (VSTM) Q4 2025 Earnings Call Transcript - The Globe and Mail

12:19 PM
pulisher
02:04 AM

Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits

02:04 AM
pulisher
12:08 PM

Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and Financial Challenges - GuruFocus

12:08 PM
pulisher
Mar 04, 2026

Verastem Q4 Earnings Call Highlights - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem: Fourth Quarter Financial Results Overview - Bitget

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem (VSTM) Reports Strong Q4 2025 Earnings and Progress in Clinical Trials - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

Key Developments for Verastem (VSTM) in 2026 Clinical Trials - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com India

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks - TipRanks

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem (VSTM) Reports Strong Revenue and Advances Cancer Treat - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem (NASDAQ:VSTM) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem: Q4 Earnings Snapshot - KVUE

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem, Inc. releases Q4 and year end 2025 results with business update - Traders Union

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem (VSTM) shares updated March 4, 2026 corporate presentation - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Earnings Summary: Verastem Q4 - Benzinga

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem (NASDAQ: VSTM) grows LGSOC launch and advances KRAS G12D programs - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Business Wire

Mar 04, 2026
pulisher
Mar 03, 2026

Earnings Outlook For Verastem - Benzinga

Mar 03, 2026
pulisher
Mar 01, 2026

VSTM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 01, 2026
pulisher
Feb 27, 2026

VSTM Should I Buy - Intellectia AI

Feb 27, 2026
pulisher
Feb 26, 2026

Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS

Feb 26, 2026
pulisher
Feb 25, 2026

Will Avmapki Fakzynja Co-Pack Drive Sustainable Growth For Verastem This Year? - RTTNews

Feb 25, 2026
pulisher
Feb 25, 2026

Verastem (VSTM) Projected to Post Earnings on Wednesday - MarketBeat

Feb 25, 2026
pulisher
Feb 23, 2026

VSTM Technical Analysis & ETF Price Forecast - Intellectia AI

Feb 23, 2026
pulisher
Feb 21, 2026

Balyasny Asset Management L.P. Increases Stake in Verastem Inc. - GuruFocus

Feb 21, 2026
pulisher
Feb 20, 2026

Verastem, Inc. (VSTM) Stock Analysis: Navigating the 179% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Feb 20, 2026
pulisher
Feb 18, 2026

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire

Feb 18, 2026
pulisher
Feb 17, 2026

What Makes Verastem (VSTM) a New Buy Stock - Yahoo Finance

Feb 17, 2026
pulisher
Feb 17, 2026

RTW holds 7.84M Verastem (VSTM) shares with ownership capped at 9.99% - Stock Titan

Feb 17, 2026
pulisher
Feb 16, 2026

Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts - MarketBeat

Feb 16, 2026
pulisher
Feb 13, 2026

Verastem, Inc. (VSTM) Investor Outlook: Unveiling A Potential 184.67% Upside In Biotech - DirectorsTalk Interviews

Feb 13, 2026
pulisher
Feb 12, 2026

Gap Down: What analysts say about Verastem Inc stock2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn

Feb 12, 2026
pulisher
Feb 11, 2026

VSTM: Strong sales, robust clinical progress, and major data updates expected mid-year - TradingView

Feb 11, 2026
pulisher
Feb 09, 2026

FY2025 EPS Estimates for Verastem Increased by HC Wainwright - MarketBeat

Feb 09, 2026
pulisher
Feb 08, 2026

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Feb 08, 2026
pulisher
Feb 07, 2026

Analysts Offer Insights on Healthcare Companies: Medical Facilities (OtherMFCSF), Bio-Techne (TECH) and Verastem (VSTM) - The Globe and Mail

Feb 07, 2026
pulisher
Feb 06, 2026

Verastem Oncology Gains Momentum Following Drug Launch and Strategic Shift () - aktiencheck.de

Feb 06, 2026
pulisher
Feb 06, 2026

Verastem, Inc. (VSTM) Stock Analysis: Exploring the 164.73% Potential Upside in Biotech Innovation - DirectorsTalk Interviews

Feb 06, 2026
pulisher
Feb 06, 2026

HC Wainwright Forecasts Verastem FY2025 Earnings - MarketBeat

Feb 06, 2026
pulisher
Feb 06, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail

Feb 06, 2026
pulisher
Feb 06, 2026

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail

Feb 06, 2026
pulisher
Feb 06, 2026

Verastem Extends Cash Runway and Highlights 2025 Results - The Globe and Mail

Feb 06, 2026
pulisher
Feb 06, 2026

Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail

Feb 06, 2026
pulisher
Feb 05, 2026

Verastem Inc (VSTM) CEO Dan Paterson Sells 970 Shares - GuruFocus

Feb 05, 2026
pulisher
Feb 05, 2026

HC Wainwright Estimates Verastem FY2030 Earnings - MarketBeat

Feb 05, 2026
pulisher
Feb 04, 2026

VSTM: HC Wainwright & Co. Assumes 'Buy' Rating with Price Target of $18.00 | VSTM Stock News - GuruFocus

Feb 04, 2026
pulisher
Feb 04, 2026

Verastem Oncology: Preliminary Q4/2025 Revenue and Business Updates; 2026 Priorities for Novel RAS/MAPK Pathway-Driven Cancer Portfolio - marketscreener.com

Feb 04, 2026
pulisher
Feb 04, 2026

Verastem Projects $17.5 Million Net Revenue for Q4 2025 - Intellectia AI

Feb 04, 2026
pulisher
Feb 04, 2026

Verastem (VSTM) Makes Strides with Innovative Cancer Treatments - GuruFocus

Feb 04, 2026
pulisher
Feb 04, 2026

Verastem (NASDAQ:VSTM) Now Covered by HC Wainwright - MarketBeat

Feb 04, 2026

Verastem Inc (VSTM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.57
price down icon 4.21%
biotechnology ONC
$292.94
price down icon 2.03%
大文字化:     |  ボリューム (24 時間):